Cannabis Extracts Can Interfere with Blood Thinners Like Warfarin — And Different Strains Vary Widely

In vitro study using pooled, mixed-gender human liver microsomes. Cannabis extracts were prepared from four chemotypes, either commercially obtained or prepared via ethanol extraction with overnight decarboxylation. Extracts were characterized for cannabinoid content using NMR and HPLC-PDA-ELSD-ESIMS. CYP inhibition was assessed using tolbutamide (CYP2C9) and testosterone (CYP3A4) as probe substrates, with warfarin, phenprocoumon, and acenocoumarol as clinically relevant model compounds.

Warfarin has one of the narrowest therapeutic windows of any commonly prescribed drug — too little and blood clots form, too much and dangerous bleeding occurs. If cannabis extracts inhibit the enzymes that metabolize warfarin, patients could unknowingly push their blood levels into the danger zone. This study shows the risk is real and varies by cannabis product type, which is especially concerning because patients rarely consult their anticoagulation clinic about cannabis use.

This study extends the CYP450 drug interaction findings from RTHC-00091 (CBD inhibiting four enzyme families in a controlled human trial) into a clinically critical medication class. While RTHC-00091 showed the general principle — CBD inhibits drug-metabolizing enzymes — this study applies it specifically to anticoagulants, where the consequences of enzyme inhibition could be life-threatening bleeding. Together with RTHC-00112 (drug-cannabinoid interactions review), these studies build a clear warning: cannabis is not pharmacologically inert, and its interactions with prescription medications deserve the same attention as any other drug-drug interaction.

In vitro study using liver microsomes — not a clinical trial in patients. Enzyme inhibition in a test tube doesn't always predict clinically significant interactions in living patients. The extracts were tested at concentrations that may or may not reflect what reaches the liver after normal cannabis use. No patient outcomes (bleeding events, INR changes) were measured. The four chemotypes represent a fraction of the enormous variety of cannabis products available.